Ocular Therapeutix appoints Michael Goldstein as CMO
Prior to joining Ocular Therapeutix, Dr. Goldstein served as Chief Medical Officer of Applied Genetic Technologies Corp (AGTC), a clinical-stage biotechnology company focused on the development of products for the treatment of rare diseases, with a focus on ophthalmology.
Before joining AGTC, he held several positions of increasing responsibility with Eleven Biotherapeutics, including Chief Medical Officer and Vice President of Clinical Research.
Since 2002, Dr. Goldstein has served as Co-Director, Cornea and External Disease Service and Assistant Professor of Ophthalmology at the New England Eye Center and Tufts University School of Medicine.
Previously, he was Director of Refractory Surgery Service and Assistant Professor of Ophthalmology at the University of Florida College of Medicine.
Dr. Goldstein has published extensively and is a reviewer for multiple ophthalmology scientific journals.
Dr. Goldstein holds an M.D. from Northwestern University Medical School, an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management, and received his B.A. in political economy from Williams College. ■
LATEST MOVES FROM Massachusetts
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
- Acer Therapeutics appoints William T. Andrews as CMO
More inside POST
Hiring data creates risk of workplace bias Leadership